Illumina Says it Has Collected Sufficient Samples for Cancer Sequencing Study; Starts Analyzing Data

The aim of the project, which is part of a three-pronged diagnostics strategy that Illumina unveiled earlier this year, is to identify "unique markers" that, upon validation, can be commercialized as diagnostic tests.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.